Insider buying
~$1.1K943 sh @ $1.15
Traded Jun 23, 2025 · filed 2 days later
The CEO of Akari Therapeutics paid $1.1K out of pocket for Akari Therapeutics shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jun 17, 2025 · Filed Jun 20, 2025
The CEO of Akari Therapeutics paid $18K out of pocket for Akari Therapeutics shares. Shares held went up 6% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$18,000
Shares × reported transaction price
<$25K
+6.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
33 days after results of May 15, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.8% | +3.0% | −2.1% |
| 30 days | −2.2% | +5.7% | −7.8% |
| 90 days | −29.4% | +11.1% | −40.5% |
| 180 days | −77.2% | +14.1% | −91.3% |
| 365 days | −74.6% | +22.2% | −96.8% |
Past results only. Not a forecast.
Insider buying
Traded Jun 23, 2025 · filed 2 days later
The CEO of Akari Therapeutics paid $1.1K out of pocket for Akari Therapeutics shares.
Insider buying
Traded Jun 24, 2025 · filed 1 day later
The CEO of Akari Therapeutics paid $6K out of pocket for Akari Therapeutics shares.
Insider buying
Traded Jun 20, 2025 · filed 4 days later
The CEO of Akari Therapeutics paid $12K out of pocket for Akari Therapeutics shares.
Abizer Gaslightwala, President & CEO's past purchases, 90 days after disclosure: 4 buys, median −42.1 pts vs S&P 500, beat it 0 of 4 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.